51 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
including the opportunity we see for our late-stage pipeline,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. “Recruitment into our clinical … in recruitment and enrollment during the latter part of Q3 and into Q4 for all ongoing clinical trials
SPEARHEAD-1 is recruiting well and remains on target
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
29 May 20
Regulation FD Disclosure
7:42am
recruitment in the low-radiation sub-study
SPEARHEAD-1
Intended to be a registrational trial
Based on the strength of the ADP-A2M4 Phase 1 data … on HLA and MAGE-A4 expression
Aim to complete SPEARHEAD-1 recruitment by 1H 2021 and launch in the US in 2022
Other trials in the MAGE-A4 program
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
% Presented at CTOS
- Data support confidence in SPEARHEAD-1 as a registrational trial -
- Projected to complete recruitment of all patients in Q1 2021
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
for recruitment of patients with synovial sarcoma or myxoid/round cell liposarcoma. Dennis has been promoted to SVP, Late Stage Development and will continue
8-K
EX-99.1
hu7rr4lhdaf769z3 oyj
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
j6oq9b
14 Mar 22
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
8:06am
8-K
EX-99.2
aiob 31jujfeu8d7m7om
10 Apr 17
Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
12:00am
8-K
EX-99.1
e3z oef84zfdpasw
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
10-Q
w48jvt 77fhv
12 May 16
Quarterly report
12:00am
10-K
9tel wortzm1bl67s8
13 Mar 17
Annual report
12:00am
8-K
EX-99.1
ffrohdwhgk bl
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am